Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms 6Leukemia, Myeloid, Acute 6Leukemia 4Carcinoma 3Hematologic Diseases 2Small Cell Lung Carcinoma 1Sarcoma, Myeloid 1Recurrence 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1Acute Disease 1

Interventions

Paclitaxel 22Carboplatin 18liposomal doxorubicin 14Bevacizumab 9Topotecan 8Docetaxel 8Gemcitabine 7Cisplatin 7rucaparib 6pembrolizumab 6mirvetuximab soravtansine 5Cyclophosphamide 5Taxes 4Albumin-Bound Paclitaxel 4sargramostim 3ixabepilone 3Cytoreduction Surgical Procedures 3CCV-AV protocol 3130-nm albumin-bound paclitaxel 3taxane 2talazoparib 2pazopanib 2olaparib 2fludarabine phosphate 2fludarabine 2denileukin diftitox 2cediranib 2catumaxomab 2belinostat 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Ovarian Epithelial × vosaroxin × Clear all
NCT00408603 2017-07-27

Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer

Sunesis Pharmaceuticals

Phase 2 Completed
183 enrolled 15 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Carcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡